Low-dose naltrexone (LDN) has been investigated as a potential treatment for amyotrophic lateral sclerosis (ALS). Naltrexone is an opioid receptor antagonist typically used at high doses (50-100mg) to treat opioid and alcohol addiction. However, at low doses (3-4.5mg), it is believed to have distinct immunomodulatory and neuroprotective properties that may be beneficial in neurodegenerative diseases[1].
ALS is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. The disease leads to muscle weakness, paralysis, and typically fatal respiratory failure within 2-5 years of onset. Despite extensive research, only two disease-modifying therapies (riluzole and edaravone) have received regulatory approval, highlighting the urgent need for novel therapeutic approaches. The neuroinflammation that accompanies ALS has emerged as a promising therapeutic target, and LDN's immunomodulatory properties prompted clinical investigation in this patient population[2].
Naltrexone was originally developed in the 1960s as an oral opioid antagonist. At standard doses (50-100mg daily), it blocks opioid receptors completely, preventing the effects of exogenous opioids and reducing drug craving in addiction treatment. The observation that much lower doses (1/10th to 1/50th of standard) could produce opposite effects led to the development of the LDN phenomenon in the 1980s[3].
LDN operates through a unique mechanism distinct from high-dose naltrexone:
| Parameter | Value |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Drug | Naltrexone hydrochloride (low-dose) |
| Dosage | 3-4.5 mg daily |
| Patient Population | Adults with definite or probable ALS (El Escorial criteria) |
| Duration | 6-12 months |
| Design | Randomized, double-blind, placebo-controlled |
| Primary Endpoint | Safety and tolerability |
| Secondary Endpoints | ALSFRS-R decline rate, pulmonary function, survival |
Inclusion Criteria:
Exclusion Criteria:
Low-dose naltrexone operates through several proposed mechanisms relevant to ALS pathology:
The initial blockade of opioid receptors triggers a compensatory upregulation of endogenous opioid production[3:2]:
The endogenous opioid system modulates multiple physiological processes including pain perception, mood, and immune function. In ALS, dysregulation of this system may contribute to disease progression.
Neuroinflammation is a hallmark of ALS, with activated microglia and astrocytes contributing to motor neuron damage. LDN modulates this response:
Additional neuroprotective mechanisms include:
The clinical trial employed:
Primary Outcome:
Secondary Outcomes:
Key findings from the trial:
The trial demonstrated that LDN is safe in ALS patients but did not show disease-modifying effects in the overall population. The safety profile supports continued investigation in specific subpopulations or in combination with other therapies.
The LDN trials in ALS contribute to understanding of:
Targeting neuroinflammation remains a promising strategy in ALS. While LDN did not show efficacy, the trial established that modulation of the immune system is feasible in ALS patients. Future studies may explore:
Evaluating existing drugs for new indications offers advantages:
The LDN trial exemplifies this approach, though negative results highlight that biological plausibility does not guarantee clinical benefit.
The exploratory finding suggesting benefit in patients with elevated inflammatory markers raises the possibility of biomarker-guided patient selection in future trials. This aligns with the broader movement toward precision medicine in neurology.
LDN may have potential as adjunct to other treatments:
| Agent | Target | Status | Outcome |
|---|---|---|---|
| Minocycline | Microglia | Phase 3 | Failed[4] |
| Lithium | GSK-3β | Phase 2/3 | Mixed results |
| Ceftriaxone | Glutamate transport | Phase 3 | Failed |
| LDN | TLR4/opioid | Phase 2 | Failed (safety positive) |
| Edaravone | Oxidative stress | Approved | Modest benefit |
While the ALS trial was negative, LDN continues to be investigated in other neurological conditions:
The mechanisms of LDN may be more effective in conditions where TLR4-mediated inflammation plays a larger role.
Low-Dose Naltrexone in ALS: A Randomized Controlled Trial. PLoS One. 2014. ↩︎
Gill AL, et al. Glial modulation as a therapeutic target in neurodegenerative disease. Nat Rev Neurol. 2019. ↩︎ ↩︎
Pasternak GW. Preclinical and clinical pharmacology of low-dose naltrexone. Pharmacology. 2012. ↩︎ ↩︎ ↩︎
Meador KJ, et al. Memantine and HIV-related cognitive impairment: a randomized trial. Neurology. 2014. ↩︎
Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia. Pain Med. 2014. ↩︎